Saturday 29 April 2017 The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares


Optibiotix - We did notice!!! Buy

By HotStockRockets | Friday 5 August 2016


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Okay, okay we did notice! In response to several reader emails we had seen that Optibiotix (OPTI) had yesterday appointed Luis Gosalbez as Director of Business Development, effective immediately. we are sure that Luis is a charming chappie and his CV looks awesome but it is not even a board appointment so its no great fuss. However....

The release reads:

Luis will join the senior management team and whilst this is not the main board (PLC), Luis may take on a board position within OptiBiotix's divisional structure as these develop into separate legal entities, as announced in OptiBiotix's strategy update on 5 July 2016.

That is a tad more interesting. The word is that the first spin-off company will start the demerger process with an RNS within weeks or a couple of months at most. As to its valuation?

Listen clearly to Steve O'Hara at UK Investor Show HERE. He could not be clearer. Yet the market cap at 74p-76p is just £61 million.

You see the potential near term upside?  Perhaps interim results out on 25 August will be the platform for demerger news? The shares remain a buy at 80p or below and we expect to be selling at well over 100p this autumn.

To catch the next share tip from HotStockRockets out shortly for just £5 click HERE


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on OPTI


Comments

Comments are turned off for this article.




Site by Everywhen